13.57 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||13.56 x 900|
|Ask||13.58 x 3200|
|Day's Range||13.51 - 13.95|
|52 Week Range||9.14 - 19.48|
|Beta (3Y Monthly)||1.28|
|PE Ratio (TTM)||19.09|
|Earnings Date||Feb 24, 2020 - Feb 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.33|
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll apply a basic...
Corcept (CORT) delivered earnings and revenue surprises of 15.79% and 5.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif., Nov. 07, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
MENLO PARK, Calif., Oct. 31, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate.
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Corcept Therapeutics Incorporated (CORT) filed a complaint against the company's officers and directors for breaches of fiduciary duty, insider selling and misappropriation of information, waste of corporate assets, and violations of the Securities Exchange Act of 1934 between August 2, 2017 and February 5, 2019. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effect of cortisol. Corcept's drug Korylm is a cortisol receptor blocker used to control hyperglycemia.
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Kimberly Park has joined the company’s Board of Directors. “I am very happy to welcome Kim to our Board,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.
Attractive stocks have exceptional fundamentals. In the case of Corcept Therapeutics Incorporated (NASDAQ:CORT...
Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the administration of Korlym® with food. The patent will expire in November 2032. “This patent covers an important finding of our research – that for optimal effect, Korlym must be taken with food,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. Upon issuance, Corcept plans to list the patent, entitled “Optimizing Mifepristone Absorption” (U.S. Pat.
Joseph Belanoff has been the CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT) since 1999. First, this article...